Clinical Trials

1,301 enrolled 16 charts

Dermatologic

Melanoma

NCT03854474 2026-03-18

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

30 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04164082 2026-03-18

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

161 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04214067 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

164 enrolled

Sarcoma

Carcinosarcoma

NCT04548752 2026-03-18

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

88 enrolled

Pancreatic Neoplasms

NCT04708418 2026-03-18

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

60 enrolled

Dermatologic

Melanoma

NCT05172258 2026-03-18

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

52 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05217446 2026-03-18

SEAMARK

107 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05353439 2026-03-18

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

18 enrolled

Small Cell Lung Carcinoma

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

1,174 enrolled

Breast Neoplasms

NCT02954874 2026-03-17

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04958239 2026-03-17

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

151 enrolled

Tumor-Agnostic

Neoplasms

NCT03485209 2026-03-16

innovaTV 207

GastrointestinalHead & NeckThoracic

352 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04083599 2026-03-16

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

DermatologicGastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05562830 2026-03-16

MK-3475-04A

48 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

83 enrolled

Breast Neoplasms

NCT06116136 2026-03-16

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

48 enrolled

Stomach Neoplasms

NCT03360890 2026-03-13

iPRIME

46 enrolled

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT03786081 2026-03-13

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

214 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05687266 2026-03-13

AVANZAR

1,350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

GastrointestinalGynecologicThoracic

750 enrolled

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06704724 2026-03-13

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT04897022 2026-03-12

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

Other solid neoplasmThoracic

7 enrolled

Mesothelioma, Malignant

NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

60 enrolled

CNS

Astrocytoma, Oligodendroglioma

NCT06635824 2026-03-12

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

191 enrolled

Lung Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

340 enrolled

Phase 4 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT05689671 2026-03-10

ANTELOPE

136 enrolled

Non-Small Cell Lung Cancer Metastatic

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

53 enrolled 10 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT04030455 2026-03-09

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

NCT04736173 2026-03-09

ARC-10

169 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06604858 2026-03-09

TELESCOPE

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02959463 2026-03-06

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Other solid neoplasmThoracic

24 enrolled 11 charts

Mesothelioma, Malignant

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

410 enrolled

Other solid neoplasm

Select Advanced Solid Tumors

NCT02362594 2026-03-05

MK-3475-054

1,019 enrolled 16 charts 1 FDA

Dermatologic

Melanoma

NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Phase EARLY_PHASE1 Active not recruiting

17 enrolled

Pathologic Complete Response

NCT04522336 2026-03-05

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

16 enrolled

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

NCT05721755 2026-03-05

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

290 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03313778 2026-03-04

KEYNOTE-603

161 enrolled

Other solid neoplasm

Solid Tumors

NCT04214249 2026-03-04

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Other hematologic neoplasm

49 enrolled 32 charts

Leukemia, Myeloid, Acute

NCT04895722 2026-03-04

MK-1308A-008

302 enrolled

Phase NA Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT02658279 2026-03-03

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

27 enrolled

CNS

Glioma

NCT06057038 2026-03-03

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors